Compare ONEW & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONEW | ADCT |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.4M | 483.1M |
| IPO Year | 2020 | 2020 |
| Metric | ONEW | ADCT |
|---|---|---|
| Price | $10.82 | $3.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $19.00 | $7.60 |
| AVG Volume (30 Days) | 196.6K | ★ 2.0M |
| Earning Date | 01-29-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,872,334,000.00 | $75,209,000.00 |
| Revenue This Year | $2.23 | $10.36 |
| Revenue Next Year | $3.55 | $3.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 5.63 | ★ 6.35 |
| 52 Week Low | $10.14 | $1.05 |
| 52 Week High | $21.00 | $4.80 |
| Indicator | ONEW | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 41.32 | 42.26 |
| Support Level | $10.14 | $3.35 |
| Resistance Level | $10.82 | $4.05 |
| Average True Range (ATR) | 0.49 | 0.22 |
| MACD | 0.11 | -0.03 |
| Stochastic Oscillator | 30.41 | 18.98 |
OneWater Marine Inc is a recreational marine retailer in the United States. The company operates in two segments: Dealership and Distribution. The Dealership segment is involved in selling new and pre-owned boats. It also arranges financing and insurance products, provides repairs and maintenance services, offers marine-related parts and accessories, and supplies slip and storage accommodations at certain locations. The Distribution segment focuses on the manufacturing, assembly, and distribution of marine-related products. These products are supplied to distributors, box retailers, and online retailers through a network of warehouses and distribution centers. The company generates the majority of its revenue from the Dealership segment.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).